Metastatic tumor cells engage the local tumor microenvironment and activate specific pro-survival mechanisms to thrive and progress in the harsh bone marrow niche. Here we show that the major contributors to the survival of carcinoma cells that have colonized the bone marrow are the adipocyteinduced oxidative stress and ER stress pathways. We demonstrate that upon exposure to adipocyte-rich environments in vitro or in vivo, bone-trophic prostate and breast tumor cells upregulate the oxidative stress enzyme, HO-1. We also show that HO-1 levels are significantly increased in human metastatic prostate cancer tissues and that stable HO-1 overexpression in tumor cells promotes growth and invasiveness. Co-incident with the adipocyte-induced expression of HO-1, there is an upregulation of ER chaperone BIP and splicing of XBP1, indicating adipocyte-driven unfolded protein response, a process that we show to be sensitive to antioxidant treatment. Importantly, we also demonstrate that triggering of the oxidative stress and ER stress responses, or HO-1 induction by adipocyte exposure result in the activation of pro-survival pathways, involving survivin. Collectively, our findings reveal a new link between HO-1 and survivin expression in tumor cells, and provide a new insight into potentially targetable survival pathways in bone-metastatic disease.
Results

HO-1, BIP and XBP1 levels are induced in prostate cancer cells interacting with adipocytes. It
has been well-established that marrow adiposity is a major contributor to tumor progression in bone [30] [31] [32] [33] . We have previously discovered that HO-1 is one of the most significantly upregulated genes in prostate bone tumors from mice with diet-induced marrow adiposity 29 . Upon further investigation, we also observed that the induction of this enzyme in response to high fat diet (HFD) occurs only in the intratibial and not in subcutaneous prostate tumors. Specifically, immunohistochemical detection of HO-1 protein clearly revealed increased HO-1 expression in tumor nests as opposed to surrounding stroma in bone tumors from HFD mice (Fig. 1A) . This was further confirmed by increased HO-1 mRNA levels using human-specific Taqman RT PCR probes (Fig. 1B) . To examine the relevance of HO-1 in human metastatic disease, we performed in silico Oncomine database analyses of several prostate datasets and determined that expression of this enzyme is higher in metastatic tissues than primary tumors from prostate cancer patients (Fig. 1C ). Additional cBioPortal polyA transcriptome analysis of RNA-seq filtered for mRNA from the Metastatic Prostate Cancer, SU2C/PCF Dream Team cohort showed that across multiple metastatic tumor sites in patients there is strikingly high expression of HO-1 in bone lesions compared to other distal sites collected ( Supplementary Figure 1) . Importantly, our own immunohistochemical staining of bone biopsy tissues from metastatic patients confirmed high HO-1 presence in the cytokeratin 18-positive (CK18+) tumor cells colonizing the bone marrow ( Fig. 1D ). Although HO-1 is predominately expressed at high levels in CK18+ areas of the bone lesion, some HO-1 expression was detected in areas of the bone marrow not occupied by the tumor (Fig. 1D, bottom panels) , which is consistent with the expression of this enzyme in normal cells 10, 14, 34 . However, the majority of HO-1 presence, and the highest intensity of staining were observed in CK18+ areas of the bone lesion. These novel findings prompted us to investigate the role of HO-1 in metastatic tumor cells in bone.
As our data clearly suggested a link between increased adipocyte numbers in bone and HO-1 expression in the skeletal tumor, we went on to determine if this is a direct effect of adipocyte exposure. We first examined HO-1 gene and protein levels in PC3 and ARCaP(M) cells grown in transwell co-cultures with marrow fat cells. Several-fold increases in HO-1 mRNA and protein levels were observed in tumor cells from transwell co-cultures as opposed to cells grown alone ( Fig. 2A,B ,D, and E). Interestingly, along with augmented HO-1 levels, there were highly prominent increases in the gene and protein expression of the ER chaperone BIP, a result suggesting an induction of ER stress ( Fig. 2A ,C,D, and F). This effect of bone marrow adipocyte-driven HO-1 and BIP induction was not specific to prostate cancer cells, as similar effects were observed in bone-seeking breast carcinoma MDA-MB-231BO cells ( Supplementary Figure 2) .
Since both HO-1 and BIP are important sensors of reactive oxygen species (ROS), and protectors from oxidative cell damage 12, 20 , we next examined whether their induction upon interaction with adipocytes was associated with oxidative stress. We used a Total ROS/Superoxide detection kit, composed of a green-fluorescent dye to measure a wide range of reactive species, such as hydrogen peroxide, peroxynitrite, hydroxyl radicals, nitric oxide, and peroxy radicals, and an orange dye to detect superoxide. We determined that total ROS levels in tumor cells were significantly higher upon transwell co-culture with adipocytes ( Fig. 3, green ), suggesting adipocyte exposure induced an oxidative stress response in the tumor cells. Interestingly, there were no significant differences in the SCIentIfIC REPORTs | (2018) 8:40 | DOI:10.1038/s41598-017-17800-5 superoxide levels (red) between culture conditions, nor in the expression of superoxide dismutase (SOD2), one of the key enzymes responsible for superoxide regulation ( Supplementary Figure 3 ). This suggests that reactive species other than superoxide (e.g., hydrogen peroxide, known as a primary ROS signaling molecule 35 Supplementary Figure 4 ) brought the levels of both HO-1 and BIP back to baseline. In addition, both NAC and GSH significantly reduced adipocyte-induced ROS production in transwell co-cultures (Supplementary Figure 5 ). This further indicates that the expression of HO-1 and BIP is indeed likely regulated by the adipocyte-induced oxidative stress.
Notably, we also observed that adipocytes induce transcript levels and splicing of X-box Binding Protein 1 (XBP1), a factor governing UPR 36, 37 , and this effect was abolished by the treatment with NAC ( Fig. 4D ). Interestingly, treatment of adipocyte-tumor cell co-cultures with Isoproterenol, an inducer of lipolysis, increased splicing of XBP1 and augmented BIP expression, indicating the importance of adipocyte-supplied lipids in ER stress induction in tumor cells (Supplementary Figure 6A) . Accordingly, adipocyte-induced XBP1 splicing was reduced by the treatment with STF 083010 and MKC3946 (Supplementary Figure 6B ,C), the inhibitors of XBP1-spicing enzyme IRE1 38, 39 .
Adipocyte-induced oxidative stress and HO-1 overexpression promote tumor cell invasion.
We have reported previously that prostate and breast tumor cells exposed to adipocyte-derived factors are significantly more invasive than cells cultured under control conditions 29 . Since adipocyte-induced invasion appears to occur in parallel with the induction of oxidative stress and UPR, we speculated that NAC treatment would reverse CK18 was used as a control for tumor cell-specific marker in the bone microenvironment. Serial sections without incubation with a primary antibody were used as a control (Inset).
SCIentIfIC REPORTs | (2018) 8:40 | DOI:10.1038/s41598-017-17800-5 this phenotype. Our analysis of PC3 and ARCaP(M) invasion through the reconstituted basement membrane (rBM) revealed significant reduction in the number of invaded cells with NAC treatment ( Fig. 5 ), suggesting that adipocyte-induced oxidative stress promotes an invasive phenotype in prostate cancer cells. It is important to note that NAC treatment at the concentration used for this study did not significantly affect tumor cell viability as indicated by the Calcein A/M viability assay, Calcein staining and the absence of PARP cleavage ( Supplementary  Figure 7 ). This further confirms that the observed effects of NAC were invasion-specific.
Since HO-1 is one of the key antioxidant enzymes induced by oxidative stress and we have shown its expression is increased upon adipocyte exposure in vitro and in vivo ( Fig. 1 and 29 ), we reasoned that its stable overexpression in tumor cells in the absence of adipocytes would be sufficient to induce invasiveness. Indeed, both PC3 and ARCaP(M) cells stably overexpressing HO-1 (Supplementary Figure 8 ) were significantly more invasive than their empty vector counterparts ( Fig. 6 ). This is consistent with previous reports linking HO-1 with invasive potential 10, 40 .
HO-1 overexpression promotes bone tumor growth in vivo. HO-1 effects on proliferation have
been controversial, as both the pro-and anti-proliferative effects of this anti-oxidant enzyme on tumor cells have been reported 16, [40] [41] [42] . Our analysis demonstrated that stable HO-1 overexpression had modest but significant proliferation-promoting effects on tumor cells in vitro (Supplementary Figure 9A ). HO-1 overexpressing cells had increased evidence of XBP1 splicing, indicating activation of ER stress pathways (Supplementary Figure 9B) . Notably, intratibial implantation of PC3 cells stably overexpressing HO-1 resulted in both significant increase in tumor growth and progression in bone ( Fig. 7A ). Similar effects on tumor growth and BIP expression were Figure 10B ).
Since HO-1 is known to be elevated under hypoxia 43 , and both HO-1 and XBP1 have been shown to regulate hypoxia-inducible factor 1-alpha (HIF-1α) in hypoxic tumor cells 44, 45 , we next examined the levels of a direct HIF-1α target, carbonic anhydrase IX (CAIX), in response to HO-1 overexpression. CAIX transcript levels were significantly higher in HO-1 tumors as compared to EV tumors ( Fig. 7B ). These data are in agreement with the in vitro results of augmented CAIX and XBP1 levels in HO-1-overexpressing tumor cells, a phenomenon further potentiated by the interaction with adipocytes ( Supplementary Figure 11 ). Immunohistochemical analyses of PC3 and ARCaP(M) tumors revealed typical membrane CAIX staining indicative of the hypoxic phenotype upon HO-1 overexpression ( Fig. 7D and Supplementary Figure 10B ).
Exposure to marrow adipocyte and HO-1 overexpression promote tumor cell survival. Both oxi-
dative stress and ER stress have been established as important mechanisms of cell survival and tumor progression [46] [47] [48] .
To determine if exposure to adipocytes and subsequent induction of HO-1 and UPR promotes tumor cell survival, we cultured prostate tumor cells alone or in transwell with adipocytes, then performed a clonogenic assay. Tumor cells grown under transwell conditions developed significantly larger and more abundant colonies than the control cells ( Fig. 8A ). In addition, the expression of pro-survival factors Bcl-xl and survivin were significantly increased upon interaction with adipocytes ( Fig. 8B ,C), although survivin mRNA levels did not significantly change.
To determine if there is a direct link between HO-1 overexpression and activation of pro-survival mechanisms, we next examined clonogenic growth and gene and protein levels of Bcl-xl and survivin in PC3 cells overexpressing HO-1 and grown with or without adipocytes in transwell co-culture. Colonies formed by the PC3-HO1 cells were larger than those formed by the PC3-EV cells, indicating increased growth and survival despite the fact that the number of colonies did not differ significantly between the two cell lines (Fig. 8D ). HO-1 overexpression alone had small but significant effect on Bcl-xl and survivin expression both at the gene and protein levels (Fig. 8E,F) . Notably, interaction of HO-1 overexpressing cells with adipocytes led to robust upregulation of Bcl-xl and survivin protein, to levels that were significantly higher than those observed in EV cells exposed to adipocytes. This adipocyte-induced survivin protein expression was not, however, reflected by changes at the gene level, in agreement with data shown for the control transwell cultures in Fig. 8B . This suggests potential To examine whether HO-1-induced survivin expression is dependent on HO-1 activity, we treated PC3-EV and PC3-HO1 cells with zinc protoporphyrin IX (ZnPP), a known HO-1 inhibitor 50 . A robust increase in survivin levels, induced by HO-1 overexpression, was eliminated by the ZnPP treatment ( Fig. 9A ). Importantly, immunohistochemical analyses revealing increased survivin protein levels upon genetically-induced or HFD-induced HO-1 expression in prostate bone tumors in vivo ( Fig. 9B ) further underscored the importance of HO-1 in survivin regulation. This is of importance as survivin is highly expressed in prostate cancer, and its levels are particularly high in metastatic tissues from prostate cancer patients (Supplementary Figure 12 ).
Discussion
Bone is a complex organ with a propensity to harbor metastatic lesions from a number of cancers, including prostate 1,2 . Despite being highly vascularized, bone tissue is very hypoxic, with oxygen concentrations generally ranging from 1-3% 51 , thus representing a uniquely harsh microenvironment for metastatic growth. Hypoxia signaling affects tumor progression by modulating tumor metabolism 6 , driving proliferation and survival, altering the behavior and phenotype of bone cells 52 , and allowing for selection of tumor cells capable of evading therapy 53 . Hypoxia is also one of the key inducers of oxidative stress and UPR [54] [55] [56] , and it is the resistance to oxidative stress and ER stress that allow malignant cells to turn on pro-survival signaling and thrive in the hostile microenvironments [57] [58] [59] .
Oxidative stress stems from the imbalance between ROS production and the cell's ability to efficiently eliminate reactive species and repair the damages. It has been consistently postulated that persistently high ROS levels combined with the compensatory increases in antioxidant enzymes promote tumor progression by inducing DNA damage and genomic instability, as well as activating pro-survival signaling in the cell 60, 61 . However, high levels of ROS can also be detrimental to cancer cells by making them susceptible to other stressors. Accordingly, it has been established that the pro-vs. anti-tumor functions of ROS molecules depend on the magnitude, persistence and site of their activation 60 . Both the approaches to induce ROS to toxic levels and the use of anti-oxidants have been explored therapeutically and a number of studies have shown the benefits of ROS inhibition in cancer therapy 60, 62, 63 . At the same time, several large clinical trials have failed to demonstrate significant therapeutic effects of antioxidants 62 . Some of those failures were attributed to non-specificity or poor bioavailability of antioxidant agents, others to the inhibition of ROS-mediated cell death 62 . Some recent laboratory studies have also suggested antioxidants can directly promote malignant transformation of cancer cells 64 and are important for tumor initiation 65 , which adds to the controversy about the ROS involvement in cancer. However, given the undeniable evidence of ROS-mediated regulation of tumor cell proliferation 62, 63, 66 , invasion and metastasis 67, 68 , as well as chemoresistance 69 and the fact that ROS-mediated pathways in the bone tumor microenvironment are poorly understood, studies are needed to address the ROS paradox in bone-metastatic disease.
One of the cell types known to contribute significant amounts of ROS are adipocytes, especially under obese conditions 70 . ROS production has been shown to increase in parallel with fat accumulation in white adipose tissue adipocytes 71 . The increased ROS levels in adipocytes have been linked to mitochondrial dysfunction and metabolic pathologies 72 . Interestingly, an accumulation of fat in pathological bone marrow was implicated in ROS production due to fatty acid oxidation 73 . Notably, growing evidence also links oxidative stress and ROS production in bone marrow with skeletal aging and bone diseases 74, 75 . However, there have not been studies to date investigating how bone marrow fat, so abundantly present in the aging or obese bone marrow [76] [77] [78] [79] [80] [81] , might be contributing to the oxidative stress in the metastatic tumor.
The studies presented herein point to adipocyte-induced oxidative stress as a major contributor to tumor survival in bone. Our data show that upon exposure to adipocyte-rich environments in vitro or in vivo, prostate tumor cells upregulate the oxidative stress enzyme HO-1, a process that can be reversed by treatment with the anti-oxidant NAC. This is in line with well-established evidence that tumor cells are capable of developing sophisticated anti-oxidant systems to survive under high oxidative stress conditions 82, 83 . Our data also demonstrate that HO-1 levels are highly induced in metastatic tissues from prostate cancer patients, and that forced expression of HO-1 in prostate tumor cells promotes tumor growth and invasion. It is important to point out that currently available Oncomine datasets do not distinguish bone metastases from other potential metastatic sites; therefore we can not explicitly state that HO-1 overexpression was restricted to bone tumors in those samples. However, given the strikingly high HO-1 expression in bone lesions revealed by cBioPortal analyses, the fact that our own immunohistochemical examination of bone tissues demonstrated high HO-1 levels in metastatic tumor cells, and the well-established evidence that more than 80% of metastatic prostate cancer patients present with bone lesions, the importance of this enzyme in bone-metastatic disease is clearly underscored.
Our findings presented herein support previous reports linking HO-1 overexpression with prostate tumor progression and aggressiveness [13] [14] [15] , while contrasting the studies that demonstrated an inverse correlation between HO-1 and tumor proliferation and invasion 16, 17 . One reason for these differences in findings is the "double sword" nature of this inducible enzyme. The primary function of HO-1 is "antioxidant" protection via degradation of pro-oxidant heme and free radical scavenging 84 . However, under certain conditions, HO-1 activity and its downstream generation of iron and carbon monoxide can lead to ROS accumulation, creating "pro-oxidant" conditions 13, 84 . This "pro-oxidant" function of HO-1 might be especially evident in the bone microenvironment, where uniquely hypoxic and harsh environmental conditions persist. A combination of hypoxia, abundance of fatty acids and lipotoxicity, as well as ER stress conditions, all come together to modulate the local redox environment and contribute to the increases in HO-1 activity, which, in a vicious cycle, further promotes oxidative stress. This indication of a bone-specific phenotype is supported by our finding of significantly induced HO-1 levels in prostate bone tumors, but not the subcutaneous tumors from mice with diet-induced obesity. Combined with patient data demonstrating high HO-1 presence in skeletal lesions, these results underscore the importance of HO-1 in metastatic disease that warrant further investigations. It is noteworthy that in addition to its enzymatic activity, HO-1 has been shown to be proteolytically cleaved and translocated to the nucleus, where it has been demonstrated to play a role in regulation of oxidant responsive transcription factors 85 . Indeed, our previous studies have shown that exposure to adipocyte-derived factors does promote nuclear localization of HO-1 in prostate tumor cells 86 . Although our present studies do reveal the importance of HO-1 activity in the regulation of survivin levels ( Fig. 9) , it is very likely that some of the pro-survival functions of the enzyme are independent of its activity. Ongoing studies in our laboratory are focusing on understanding the importance of both mechanisms in metastatic disease.
In addition to its involvement in oxidative stress regulation and protection, HO-1 has reported links to UPR and ER stress 18 . Indeed, our data reveal that co-incident with the induction of HO-1 upon adipocyte exposure, there is a significant escalation in the levels of ER chaperone BIP as well as increases in spliced XBP1, a finding indicating activation of UPR and linking oxidative stress and ER stress pathways in a context of adipocyte-driven tumor promotion. Our observation that both adipocyte exposure and HO-1 overexpression induce splicing of XBP1, a substrate of ER-localized transmembrane sensor IRE1 36 , is of importance. It is the spliced form of XBP1 that is known to act as a potent transcriptional regulator of UPR genes such as BIP, and a promoter of tumor cell survival 87 . Both XBP1 and its spliced form have been reported to be upregulated in several cancers, and the inhibition of IRE1/XBP1 pathway has been explored therapeutically 38, 88 . Importantly, splicing and activation of XBP1 and its complex formation with HIF-1α was recently shown to enhance a hypoxic phenotype and subsequently promote the progression of triple negative breast cancers 45 . The XBP1/HIF-1α complex binds to and regulates genes associated with the Warburg phenotype 45 , and XBP1 silencing abrogates the glycolytic phenotype of gliomas 89 . We have shown previously that adipocytes promote oxygen-independent HIF-1α activation in prostate cancer cells and that HIF-1α signaling is responsible for adipocyte-induced glycolytic phenotype 6 . This suggests that adipocytes engage hypoxia and ER stress signaling pathways to support tumor growth in bone.
Another key finding from our study is that both stable overexpression of HO-1 and its induction by adipocytes result in increased levels of pro-survival factors, particularly survivin. Intriguingly, treatment of HO-1 overexpressing cells with HO-1 inhibitor ZnPP brings the survivin levels back to baseline, suggesting the importance of HO-1 activity in survivin regulation. Survivin is a member of the inhibitor of apoptosis protein (IAP) family, known to be regulated by HIF-1α, and its function is required to maintain cell viability under hypoxic conditions [90] [91] [92] . Our previous studies have established that HIF-1α is activated by adipocytes in prostate bone tumors 6 . Interestingly, one important feature of HIF-1α is that its stability can be regulated by carbon monoxide (CO) levels 93 , and CO is a product of HO-1 activity 10 . It is plausible that HO-1 overexpression, and subsequent increase in HO-1 activity, stabilize HIF-1α in tumor cells, driving downstream effects on pro-survival signaling. Our observed increases in levels of CAIX, a direct target of HIF-1α, upon HO-1 overexpression support this possibility. Survivin is expressed in almost all cancers and has been shown to be an important player in tumor aggressiveness and chemoresistance 94 . Our own Oncomine analysis of several prostate datasets revealed that its expression is particularly high in metastatic tissues as compared to primary tumors. A recent study in neuroblastoma revealed that survivin's role in chemoresistance stems from its ability to shift tumor metabolism from oxidative phosphorylation to aerobic glycolysis 95 . This is highly relevant to bone metastatic tumors, which we have shown to undergo a metabolic switch to Warburg metabolism under conditions of increased marrow adiposity 6 . Understanding how these metabolic, ER stress, and survival pathways converge in a context of bone metastatic disease, and what the role of HO-1 is in survivin regulation, is of importance and warrants further investigations.
We focused our studies on prostate cancer because we have previously established the importance of marrow adiposity in growth and progression of these tumors in the skeleton 6, 29, 30, 96 . However, our data in breast cancer bone-seeking cells MDA-MB-231BO cells suggest that this phenomenon extends beyond prostate cancer and may be relevant to other bone-trophic cancers. This could be of importance therapeutically, as all skeletal metastases share a common challenge of being incurable and difficult to treat. Our study identified HO-1 as an important driver of metastatic progression in bone. Inhibition of this enzyme as an approach to sensitize cancer cells to therapies has been extensively explored 12, 13, [97] [98] [99] and has shown to be challenging, as HO-1 is capable of protecting tumor cells from death by both inhibiting apoptosis and autophagy induced by chemotherapeutic agents 42 . Several small molecule inhibitors have shown some success in increasing sensitivity to therapy in myeloid leukemias 100 , and some strategies in targeting HO-1 metabolites have also been proposed 12 , but more studies are needed to understand the therapeutic potential of HO-1 inhibition.
As evidence of multifaceted roles for HO-1 in cancer increasingly builds, there is a growing need for further exploration of molecular mechanisms behind the action of this powerful enzyme. Data presented herein uncover its involvement in adipocyte-driven regulation of pro-survival signaling in skeletal tumors. To our knowledge, this is the first study placing HO-1 at the cross-talk between oxidative stress, ER stress and survival pathways in metastatic progression in bone. Our findings identify survivin as a target of HO-1 and a mediator of adipocyte-induced survival in the metastatic niche. These findings have clinical implications, as survivin-overexpressing tumors have recently been shown to be sensitive to glycolysis inhibitors 95 . Understanding the molecular interactions between metabolic and stress pathways represents an important step towards improved treatment options for metastatic disease.
Materials and Methods
Materials. Delbecco's modified Eagle's medium (DMEM), RPMI-1640 medium (RPMI), minimum essential medium (MEMα), Protoporphytin IX zinc(II) (ZnPP), glutathione, isoproterenol, and other chemicals, unless otherwise stated, were obtained from Sigma Aldrich (St. Louis, MO, USA). HyClone fetal bovine serum (FBS) was from ThermoFisher (Pittsburg, PA, USA). Trypsin-EDTA, Alexa Fluor 488-conjugated goat anti-rat and anti-rabbit IgG, Hoechst Dye, and Gentamicin (G418) were from Invitrogen (Carlsbad, CA, USA). StemXVivo Adipogenic Supplement and goat anti-human/mouse heme oxygenase (HO-1) was from R&D Systems (Minneapolis, MN, USA). Rosiglitazone and N-acetylcysteine (NAC) was from Cayman Chemical Company (Ann Arbor, MI, USA). ROS-ID Total ROS detection kit was from Enzo (Farmingdale, NY, USA). PureCol collagen type I was from Advanced Biomatrix (San Diego, CA, USA). Cultrex ™ (rBM; reduced growth factor) was from Trevigen (Gaithersburg, MD, USA). Transwell systems (Costar ™ Transwell ™ Permeable Supports with 0.4 µm pore size) and Falcon ™ Cell Culture Inserts (invasion chambers with 8.0 µm pore size) were from Corning (Corning, NY, USA). RNeasy Mini Kits, RNeasy Plus Mini Kits, and QIAshredders were from Qiagen (Valencia, CA, USA). Immunoblotting Luminata Forte Western HRP substrate was from EMD Millipore (Billerica, MA, USA). Z-Fix was from Anatech, LTD (Battle Creek, MI, USA). Rabbit anti-human BIP, rabbit anti-human Bcl-xl, rabbit anti-human Survivin, rabbit anti-human PARP, and rabbit anti-human XBP-1s were from Cell Signaling Technologies (Danvers, MA, USA), and rabbit monoclonal carbonic anhydrase 9 (CAIX) was from Abcam (Cambridge, MA, USA). Mouse anti-human tubulin was from Developmental Studies Hybridoma Bank. University of Iowa, and mouse anti-human cytokeratin 18 (CK18) was from Dako (Utrecht, Netherlands). STF-083010 and MKC-3946 were from Calbiochem (San Diego, CA, USA). Cell Lines. PC3 cells, an androgen-independent osteolytic cell line derived from a bone metastasis of a high-grade adenocarcinoma, were purchased from American Type Culture Collection (ATCC; Manassas, VA, USA). ARCaP(M) cells, an androgen-repressed metastatic prostate cancer M ('Mesenchymal' clone) cells, were purchased from Novicure Biotechnology (Birmingham, AL, USA). Both lines were stably transfected with empty vector (E) and HO-1 (H) via myc-DDK vector plasmids (OriGene, Rockville, MD), which contain the neomycin-resistant gene. Transfection was performed using Lipofectamine 2000 and stable clones were selected, expanded, and maintained in medium supplemented with G418 (400 µg/ml for PC3, 800 µg/ml for ARCaP(M)). The MDA-MB-231BO is a bone-seeking clone derived from MDA-MB-231 breast carcinoma cells and was kindly provided by Dr. Toshiyuki Yoneda (University of Texas Health Science Center, San Antonio, TX). PC3 and MDA-MB-231BO cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS, 10 mM HEPES, and 100 U/ml penicillin-streptomycin. ARCaP(M) cells were cultured in RPMI-1640 medium supplemented with 5% FBS, 10 mM HEPES, and 100 U/ml penicillin-streptomycin. Human cell lines have been authenticated by by the WSU Genomics facility.
Primary mouse bone marrow stromal cells (mBMSC) were isolated from tibiae and femurs of 6-to 8-week old FVB/N mice according to previously established protocols. To induce bone marrow adipocyte differentiation, mBMSCs were plated in 3D Collagen I gels, grown to confluency for 48-72 h, and treated with adipogenic cocktail (30% StemXVivo Adipogenic Suppliment, 1 µM insulin, 2 µM Rosiglitazone; DMEM and 10% FBS) for 8-10 days as previously described. Differentiated bone marrow adipocyte cultures were washed 3 times with PBS and used in experiments, or serum-starved overnight for collection of adipocyte-conditioned media (Adipo CM). All cells were maintained in a 37 °C humidified incubator ventilated with 5% CO 2 and were routinely tested for the presence of mycoplasma. Bone histomorphometry and tumor size. Longitudinal sections (5 µm thick) from the control and tumor-bearing tibiae were deparaffinized and stained with hematoxylin and eosin, as described previously 29, 101 . Digital images were captured under 4x magnification using an Olympus BX43 upright light microscope with an Olympus UC50 (CCD chip) camera (Olympus Scientific Solutions, Waltham, MA). The entire area of each tibia was reconstructed from the 4x images. Transwell co-culture. The mBMSC cells were embedded in Collagen, plated in 6-well plates and differentiated into adipocytes according to our previously published protocols 6, 29 . Briefly, collagen-embedded mBMSCs were grown to confluency for 48-72 hours and treated with adipogenic cocktail (30% StemXVivo Adipogenic Suppliment, 1 μM insulin, 2 μM Rosiglitazone; DMEM and 10% FBS) for 8-10 days. After mature adipocyte cultures were established, tumor cells were seeded on top of a Transwell filter (0.2 µm pore size) to allow sharing of soluble factors between the two cell types. After 48-hour co-culture, cells were washed with PBS and collected for RNA and protein analyses. For RNA extraction, tumor cells were trypsinized, and adipocytes were dissociated from collagen using 0.1% collagenase. Both cell types were then collected into RLT Plus buffer. RNA was purified following the protocol in the RNeasy Plus Mini Kit. For protein collection, cells were washed three times with PBS, trypsinized, and lysates re-suspended in SME buffer with protease (MBL International, Woburn, MA) and phophatase (Thermo Scientific, Waltham, MA) inhibitors.
Animals. All experiments involving
SCIentIfIC REPORTs | (2018) 8:40 | DOI:10.1038/s41598-017-17800-5 ROS/Superoxide Staining. Tumor cells were plated on Cultrex-coated coverslips (thin layer only) in a 24-well plate at a density of 50,000/coverslip. Cells were given several hours to attach to coverslips, then transferred to the top of a Transwell filter over adipocytes (Transwell) or into an empty 6-well plate (Control) (2 coverslips/well), making sure there were extra coverslips for positive and negative controls. Cells were incubated for a total of 48 hours prior to imaging. The night before imaging, half of the wells had 5 mM NAC added to inhibit reactive oxygen species (ROS). The day of imaging, wells were changed to fresh media. A negative control coverslip was treated with 5 mM NAC for 30 minutes prior to induction. Cells were then incubated for an hour at 37 °C with the induction solution -2x ROS Detection Solution in phenol red-free media using Oxidative Stress Detection Reagent and Superoxide Detection Reagent at a final concentration of 2.5 µM each. For positive control, pyocyanin, a ROS inducer, was added to one of the coverslips. The coverslips were washed 2x with provided wash buffer, and images were captured with a Zeiss LSM 780 confocal microscope (Carl Zeiss AG, Göttingen, Germany) using a 40x immersion lens. Oxidative stress was captured using excitation of 490 nm and emission of 525; Superoxide detection was captured using excitation of 550 nm and emission of 620 nm.
Cell Viability Assays. MTT Assay. Vybrant ® MTT cell proliferation assay (Life Technologies) was used to determine the difference in tumor cell proliferation. Clones were seeded in a clear 96-well plate at a density of 5,000 cells/well in 200 µl growth media. After 48 hours of incubation, the conversion of MTT (3-(4,5-dimet hylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) to formazan by viable tumor cells was measured at 540 nm according to manufacturer's instructions.
Calcein AM Assay. Calcein AM Assay (Trevigen) was used to assess cell viability in the presence of increasing concentrations of NAC. Cells were seeded in black-walled 96-well plates at a density of 5,000 cells/well, along with NAC, in 200 µl growth media. After 48 hours of incubation, calcein AM was applied per manufacturer's instructions, and the plate was read at an excitation of 490 nm and emission of 520 nm.
Calcein AM Cell Staining. Calcein AM cell staining was preformed to optically validate the viability of cells grown under NAC conditions. Cells were seeded on coverslips in 24-well plates at a density of 50,000 cells/coverslip, along with NAC, in 1 ml growth media. To stress cells, 0.4 µM Staurosporine was added overnight. After 48 hours of incubation, cells were stained with 2 µM Calcein AM in PBS at room temperature for 30 minutes, then gently washed and imaged on a Zeiss LSM 780 confocal microscope using excitation of 488 nm and emission of 515 nm.
Immunoblot analyses. Lysate and media samples were loaded based on DNA concentrations in the corresponding lysates and proteins were electrophoresed on 12% or 15% SDS-PAGE gels, transferred to PVDF membranes (Bio-Rad, Hercules, CA, USA) and immunoblotted for HO-1, BIP, Bcl-xl, Survivin, XBP1s, Tubulin (1:2000), PARP, and β-actin (1:1000). All horseradish peroxidase-labeled secondary antibodies were used at 1:10,000. All images are in compliance with the digital image and integrity policies. For cropped blots, full size images are included as part of supplementary material.
TaqMan RT-PCR. The cDNA from cells and in vivo samples was prepared from 1-2 µg of total RNA using High-Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City, CA, USA). The analyses of genes were performed using TaqMan ® Individual Gene Expression assays for Human HO-1 (Hs01110250), BIP (Hs00607129), CAIX (Hs00154208), Bcl-xl (Hs00236329), BIRC5/survivin (Hs04194392), SOD2 (Hs00167309), Epcam (Hs00901885), and XBP1 (Hs00231936). Assays were done on three biological replicates using TaqMan ® Fast Universal PCR Master Mix and 50 ng of cDNA/well. All reactions were run on an Applied Biosystems StepOnePlus ™ system. Three biological replicates of each sample were pooled together and assays were run in at least triplicate. All data were normalized to hypoxanthine phosphoribosyltransferase (HPRT1; Hs02800695) or 18 S (Hs03003631). DataAssist ™ Software (Applied Biosystems) was used for all analyses..
XBP-1 splicing PCR.
PCR was used to evaluate the relative expression levels of XBP-1 splicing. Human XBP-1 primer sequences are; 5′-CCTGGTTGCTGAAGAGGAGG-3′ and 5′-CCATGGGGAGATGTTCTGGAG-3′. β-actin was used as the loading control with the primer sequence; 5′-GGATGCAGAAGGAGATCACTG-3′ and 5′-CGATCCACACGGAGTACTTG-3′ (primers from Integrated DNA Technologies, Coralville, IA, USA). PCR products were run on 4% Agarose gels. PCR products were imaged using Luminescent Image Analyzer LAS-1000 Plus.
Invasion assays. Tumor cells were serum starved overnight and seeded on top of the BD invasion filter (8 µm pore size) coated with 3-D Culture Matrix ™ reduced growth factor basement membrane extract (0.1 mg/ ml). Cells were seeded at the density of 1 × 10 5 cells/filter in serum-free media. Media containing the normal growth amount of serum (10% FBS for PC3 cells, 5% FBS for ARCaP(M) cells) was added to the bottom chamber as a chemoattractant. Cells were allowed to invade for 24 hours and then filters were fixed and stained with Kwik-Diff Staining reagents (Thermo Scientific). Invaded cells were visualized and captured using an Olympus BX43 upright light microscope under 10x magnification, and were manually counted using ImageJ software (National Institutes of Health, Bethesda, MD). Data were collected from at least three independent experiments preformed in triplicate.
Clonogenic assays. Tumor cells were grown in alone or transwell conditions with adipocytes for 48 hours, then harvested with 0.25% Trypsin-EDTA and counted. Cells were plated in a 6-well plate at a concentration of 400 cells/well in regular growth media and allowed to grow for 14 days, with media replenishment occurring after 7 days. Cells were then fixed with cold methanol and stained with 0.1% Crystal Violet at room temperature. Stain was washed off with tap water and images were captured using a cell phone camera.
Oncomine analyses. The Oncomine database (Oncomine ™ v4.5: 729 datasets, 91,866 samples) was used for the analysis of primary (P) vs. metastatic (M) tumors by employing filters for selection of conditions and genes of interest (prostate cancer; metastasis vs. primary; genes). Data were ordered by 'overexpression' and the threshold was adjusted to P-value < 1E − 4; fold change, 2; and gene rank, top 10%. For each database, only genes that met the criteria for significance were reported. cBioPortal analysis. The cBioPortal for Cancer Genomics 102,103 was utilized to assess HMOX1 mRNA expression in patient metastatic prostate tumors. Using the Metastatic Prostate Cancer, SU2C/PCF Dream Team cohort 104 , we performed a query for HMOX1. We then plotted HMOX1 mRNA expression against the clinical attributes "Sample Type" and "Tumor Site", allowing us to examine the levels of HMOX1 expression (Y Axis) across metastatic prostate cancer patients presenting in various metastatic sites, including bone (X Axis). mRNA was isolated in this cohort by PolyA selection and data are shown as log2 scaled analysis of RNA Seq Reads per Kilobase Million (RPKM).
Statistical analyses. For all analyses, data were presented as mean of at least 3 experiments ± SD and statistically analyzed using unpaired student T-test. For three or more groups, one-way analysis of variance was used.
